Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9253861 | 0.83 | CYP3A4 (0.43) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL27792203 | 0.79 | MAPT (0.45) | SMN1; SMN2CYP3A4CYP2C19KMT2ACYP2C9 | |
| SCHEMBL14639112 | 0.77 | CD38 (0.46) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28678423 | 0.77 | CYP3A4 (0.59) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL709619 | 0.75 | LMNA (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19KMT2A | |
| SCHEMBL12804219 | 0.75 | MAPT (0.42) | SMN1; SMN2CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL10764415 | 0.74 | KMT2A (0.47) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8815628 | 0.74 | GAA (0.50) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL21863403 | 0.74 | CYP3A4 (0.46) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30753599 | 0.74 | LMNA (0.56) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325364-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | NOTTINGHAM TRENT UNIVERSITY (GB) | 2024-10-03 | — | — | US | claimed |
| EP-4370119-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | Nottingham Trent University (GB) | 2024-05-22 | — | — | EP | claimed |
| WO-2023285789-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | NOTTINGHAM TRENT UNIVERSITY (GB) | 2023-01-19 | — | — | WO | claimed |
| US-20240325364-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | NOTTINGHAM TRENT UNIVERSITY (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4370119-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | Nottingham Trent University (GB) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023285789-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | NOTTINGHAM TRENT UNIVERSITY (GB) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325364-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | ACSL3, APOL1, PFKL | SMN1; SMN2 2324/4885CYP1A2 1014/4885CYP3A4 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.